国家一类新药盐酸埃克替尼的药理与临床评价  

Pharmacology and clinical evaluation of icotinib hydrochloride

作　　者：谭芬来 张力[2] 赵琼[3] 刘东阳[4] 胡云雁 刘勇 丁列明 胡蓓[4] 王印祥 

机构地区：[1]浙江贝达药业,杭州311100 [2]北京协和医院呼吸科,北京100730 [3]浙江大学医学院附属第一医院呼吸科,杭州310003 [4]北京协和医院临床药理基地,北京100730

出　　处：《中国新药杂志》2009年第18期1691-1694,共4页Chinese Journal of New Drugs

摘　　要：盐酸埃克替尼(icotini bhydrochloride,克美纳TM,浙江贝达药业有限公司生产,规格:100,125,150,200mg)是一种新型口服表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs),临床用于治疗既往接受过1种或2种化疗的局部晚期或转移的非小细胞肺癌。文中对盐酸埃克替尼在中国的I～IIa期临床试验进行了总结,并对其药理作用、药动学、临床和安全性评价进行了综述。lcotinib hydrochloride is a novel oral epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI）. It is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer （NSCLC） previously treated with one or two chemotherapy. Several phase Ⅰ and Ⅱa trials in both healthy volunteers and NSCLC patients have been conducted in China recently. In this review we summarized the brief results from these trials, the pharmacology and pharmacokinetics of icotinib hydrochloride.

关 键 词：盐酸埃克替尼 非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 药理学 药动学 

分 类 号：R983[医药卫生—药品] R979.1[医药卫生—药学]